AbbVie
ABBV
$167.72
Share price
-0.04%
Change (1 day)
2.22%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - Total debt
Total debt on the balance sheet as of December 2023 : $59.38 B
According to AbbVie's latest financial reports the company's total debt is $59.38 B. A company’s total debt is the sum of all current and non-current debts.
AbbVie - Total debt on balance sheet (from 2011 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $59.38 B | -6.14% |
| 2022-12-31 | $63.27 B | -17.49% |
| 2021-12-31 | $76.68 B | -10.89% |
| 2020-12-31 | $86.05 B | 28.97% |
| 2019-12-31 | $66.72 B | 65.54% |
| 2018-12-31 | $40.31 B | 7.87% |
| 2017-12-31 | $37.36 B | 1.43% |
| 2016-12-31 | $36.84 B | 16.33% |
| 2015-12-31 | $31.67 B | 111.46% |
| 2014-12-31 | $14.97 B | 1.73% |
| 2013-12-31 | $14.72 B | -6.06% |
| 2012-12-31 | $15.67 B | 32550% |
| 2011-12-31 | $48 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $70.84 B | 19.30% | 🇺🇸 USA |
 Eli Lilly LLY | $25.22 B | -57.52% | 🇺🇸 USA |
 Amgen AMGN | $64.61 B | 8.80% | 🇺🇸 USA |
 Biogen BIIB | $7.33 B | -87.64% | 🇺🇸 USA |
 Gilead Sciences GILD | $24.98 B | -57.92% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $41.46 B | -30.18% | 🇺🇸 USA |
 AstraZeneca AZN | $28.62 B | -51.80% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $22.93 B | -61.38% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $0.42 B | -99.28% | 🇺🇸 USA |